---
layout: default
title: Activated Charcoal Arnica Montana Cicuta Virosa Ro
parent: 僅模型預測 (L5)
nav_order: 201
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arnica Montana Cicuta Virosa Ro
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Homeopathic Multi-Ingredient Combination: No TxGNN Repurposing Prediction Available

## One-Sentence Summary

This submission contains an 11-ingredient combination spanning conventional and homeopathic substances — Activated Charcoal, Arnica Montana, Cicuta Virosa Root, Euphorbia Resinifera Resin, Goldenseal, Kerosene, Lead, Lycoperdon Utriforme, Oyster Shell Calcium Carbonate, Phosphorus, and Sulfur.
The TxGNN model returned **no repurposing predictions** for this combination, as no DrugBank mapping could be established and no original indications are on record.
There are **0 clinical trials** and **0 publications** identified to support any new indication.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no regulatory data found in any jurisdiction |
| Predicted New Indication | None |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — no predictions generated; model could not map this compound |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this compound. This outcome is expected for three structural reasons.

First, the submission consists of **11 distinct ingredients**, the majority of which are classically homeopathic in nature — Arnica Montana, Cicuta Virosa, Phosphorus, Sulfur, Lead (Plumbum metallicum), and Oyster Shell Calcium Carbonate (Calcarea carbonica). TxGNN's knowledge graph is constructed around single active pharmaceutical ingredients with defined molecular targets and measurable pharmacodynamic profiles. Multi-ingredient homeopathic combinations typically lack the structured pharmacological data required for graph-based node embedding and disease link prediction.

Second, **no DrugBank ID** was resolved for this combination. Without a corresponding node in the TxGNN knowledge graph, the model has no anchor point from which to traverse disease edges or generate scored predictions. This is a prerequisite for any TxGNN output.

Third, the **mechanism of action is undefined**. Homeopathic preparations operate under principles that are distinct from conventional pharmacology, and the current TxGNN architecture cannot bridge homeopathic theory to target-based repurposing candidates.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This combination product has no US market authorization. Zero NDA applications were identified across all queried sources.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **⚠ Flagged Components:** This combination lists **Lead** and **Kerosene** as ingredients. Regardless of homeopathic dilution levels claimed, both substances carry well-established toxicological profiles. Any downstream clinical development pathway — even for a homeopathic indication — must explicitly address the intended dilution factors, route of administration, and applicable regulatory safety thresholds for these two components before evaluation can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model cannot generate repurposing predictions for this submission because the combination product lacks a DrugBank identifier, has no mapped mechanism of action, and is structurally incompatible with graph-based pharmacological inference. There is no basis to advance this candidate through a standard drug repurposing pipeline in its current form.

**To proceed, the following is needed:**

- **Clarify the submission scope**: Determine whether individual pharmacologically active components (e.g., Activated Charcoal, Goldenseal/Berberine, Euphorbia resinifera/Resiniferatoxin) should each be evaluated independently through TxGNN rather than as a pooled combination
- **Obtain DrugBank IDs** for any components with a conventional pharmacological profile; this is a hard prerequisite for any TxGNN analysis
- **Provide regulatory context**: Clarify whether this product originates from a homeopathic product database or a conventional drug registry — if the former, a different evaluation framework (e.g., traditional medicine evidence synthesis) should replace TxGNN
- **Conduct a toxicological pre-screen** for Lead and Kerosene content, with documented dilution factors, before any clinical development consideration
- **Re-submit as single-entity candidates** if the goal is graph-based repurposing: each active ingredient should be evaluated separately with its own DrugBank ID and known indication profile
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

